A comparison of sodium picosulphate ('Laxoberal') with standardised senna ('Senokot') in geriatric patients


Southampton General Hospital and Basingstoke District Hospital, England

Received: 12th November 1974

Summary

A comparison was made between the effectiveness of sodium picosulphate and that of standardised senna in a group of 50 long-stay geriatric patients. Both were found to be equally effective as laxatives, but there were wide variations in the responses of individual patients to these agents. Side-effects were uncommon. They may well have been reduced further if a small starting dose of sodium picosulphate had been used.

Key words: Laxatives – sodium picosulphate – senna – geriatrics

Introduction

Old people often appear to be preoccupied with colonic function. This was illustrated by one study where 66% of nonagenarians in the community were found to be on laxatives. Defunct medical theories on colonic auto-intoxication have probably contributed to this. Another factor is the age-related decline in gastrointestinal transit times. This is often mistakenly treated as a manifestation of constipation. For these reasons there seems little doubt that many fit elderly people are needlessly habituated to large doses of laxatives.

The picture is rather different when scrutiny is shifted to sick and disabled old people. Immobility has an important effect in inducing rectal and colonic stasis. This is all too frequently followed by faecal impaction. The patient is then only a short step away from frank faecal and urinary incontinence. Laxatives may thus play an important part in relieving disabled patients from a considerable amount of embarrassment and distress and reducing the heavy nursing and domestic load imposed on relatives supporting them.

A wide range of substances is available for the treatment of constipation. They include hydrophilic bulking agents, stool softeners and laxatives with a local irritant effect on the colon. Most preparations in the first two groups are open to theoretical and practical objections in the elderly. Irritant agents include the anthracene and polyphenolic derivatives. Examples include standardised senna, calcium sennosides, and bisacodyl. These drugs are effective laxatives producing little habituation and, because of low absorption, causing little systemic toxicity.

Another recently developed polyphenolic laxative is sodium picosulphate

*Senior Lecturer in Geriatric Medicine; **Consultant Physician in Geriatrics
A comparison of sodium picosulphate ('Laxoberal') with standardised senna ('Senokot') in geriatric patients

('Laxoberal'). This is a sulphuric ester of bis-(p-hydroxyphenyl)-pyridyl-2-methane. Animal work suggested that it might prove to be a potent laxative with a low systemic toxicity.\textsuperscript{12} Clinical trials have supported these conclusions.\textsuperscript{10,13-15} The present paper describes a comparison between this drug and standardised senna in the elderly population suffering from severe disability.

Methods
Subjects were selected from patients in two long-stay hospitals who were receiving treatment for chronic constipation. After selection each patient was given a study number. This, when related to a sealed code, indicated whether the patient was to be given standardised senna tablets or sodium picosulphate liquid. Any subject with faecal impaction was treated with suppositories or enemas and only included in the trial once the lower bowel was clear.

The initial starting dose of sodium picosulphate was 20 ml. (10 mg.) in the evening. Nursing staff were instructed to increase or decrease the daily dose by intervals of 5 ml. depending upon the previous response. Half way through the study the starting dose was reduced to 15 ml. It was felt that the higher dose was producing too brisk a response. The starting dose for standardised senna was 2 tablets in the evening. Nursing staff again increased or decreased this by 1 tablet at intervals dependent on response. Both agents were given over the course of 2 weeks.

During the study, the nursing staff recorded details on the frequency, timing and consistency of bowel motions. They also noted the onset and outcome of any side-effects.

Results
Twenty-five patients on sodium picosulphate and 25 on standardised senna were included in the study. Table I details the sexes, ages and principle diagnoses for people in the two groups. Two of the subjects on sodium picosulphate were excluded from further analysis. One, though agreeing to participate, refused to take the laxative on the first day of the trial. In the other case, as a result of a

\begin{table}
\centering
\begin{tabular}{l|c|c}
\hline
Patients & Sodium & Standardised \\
& picosulphate & senna \\
\hline
Males & 6 & 8 \\
Females & 19 & 17 \\
Median age (years) & 79 & 78 \\
\hline
\end{tabular}
\caption{Details of 50 subjects included in the study}
\end{table}

\textit{Diagnosis:}
\begin{itemize}
\item Dementia: 10 & 12 \\
\item Cerebrovascular disease: 6 & 5 \\
\item Other neurological disease: 2 & 4 \\
\item Arthritis: 4 & 2 \\
\item Others: 3 & 2 \\
\end{itemize}

trade mark Boehringer Ingelheim Ltd.
\textsuperscript{†}Each tablet contained sennosides A and B equivalent to 7.5 mg. sennoside B

642
recording error, no information was collected on the nature of bowel motions during the course of the study. One of the patients on standardised senna refused to continue on the drug during the second week of the trial. Information collected during the first week, however, was used for further analysis.

A comparison was made between the number of bowel actions per day produced by sodium picosulphate and those associated with standardised senna, (Table II). Sodium picosulphate resulted in significantly more actions during the first 2 days of treatment. Throughout the rest of the study period the figures associated with the two agents were almost identical. It should be noted that the mean dose of sodium picosulphate was considerably reduced over the first few days. That for standardised senna remained relatively constant over the 2-week observation period.

Table II. Number of bowel actions related to dose of laxative

<table>
<thead>
<tr>
<th>Response</th>
<th>Mean number of bowel actions</th>
<th>Mean dose of laxative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sodium picosulphate</td>
<td>Standardised senna</td>
</tr>
<tr>
<td>No. of patients</td>
<td>23</td>
<td>25</td>
</tr>
<tr>
<td>Day 1</td>
<td>1.26</td>
<td>0.60</td>
</tr>
<tr>
<td>Day 2</td>
<td>1.30</td>
<td>0.64</td>
</tr>
<tr>
<td>Day 3</td>
<td>0.78</td>
<td>0.72</td>
</tr>
<tr>
<td>Day 4</td>
<td>0.65</td>
<td>0.68</td>
</tr>
<tr>
<td>Day 5</td>
<td>0.74</td>
<td>0.84</td>
</tr>
<tr>
<td>Day 6</td>
<td>0.87</td>
<td>0.60</td>
</tr>
<tr>
<td>Day 7</td>
<td>0.61</td>
<td>0.50</td>
</tr>
<tr>
<td>Day 8</td>
<td>0.61</td>
<td>0.71</td>
</tr>
<tr>
<td>Day 9</td>
<td>0.43</td>
<td>0.38</td>
</tr>
<tr>
<td>Day 10</td>
<td>0.61</td>
<td>0.58</td>
</tr>
<tr>
<td>Day 11</td>
<td>0.65</td>
<td>0.75</td>
</tr>
<tr>
<td>Day 12</td>
<td>0.26</td>
<td>0.67</td>
</tr>
<tr>
<td>Day 13</td>
<td>0.48</td>
<td>0.58</td>
</tr>
<tr>
<td>Mean</td>
<td>0.71</td>
<td>0.63</td>
</tr>
<tr>
<td>Range</td>
<td>0 to 30</td>
<td>0 to 2</td>
</tr>
</tbody>
</table>

The results given in Table II are mean values. This conceals the fact that there was wide individual variation in the dosage of sodium picosulphate. The drug, after initial titration, was occasionally stopped and only recommenced when bowel function became unsatisfactory. There was much less variation in the dosage of standardised senna.

Table III compares the proportions of hard and loose motions in the two groups and in the sodium picosulphate group there was significantly more loose or un-

Table III. Consistency of motions

<table>
<thead>
<tr>
<th>Agent</th>
<th>Hard</th>
<th>Soft</th>
<th>Loose or unformed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>Sodium picosulphate</td>
<td>19</td>
<td>9</td>
<td>101</td>
</tr>
<tr>
<td>Standardised senna</td>
<td>30</td>
<td>15</td>
<td>126</td>
</tr>
</tbody>
</table>

χ² = 23.15  p < 0.001
formed motions and fewer hard motions compared with standardised senna. The consistency of motions for the two groups of patients remained relatively constant through the 2-week period of observation, (Table IV).

Table IV. Proportion of bowel motions which were loose or unformed

<table>
<thead>
<tr>
<th>Agent</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
<th>Day 8</th>
<th>Day 9</th>
<th>Day 10</th>
<th>Day 11</th>
<th>Day 12</th>
<th>Day 13</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium picosulphate</td>
<td>0.45</td>
<td>0.50</td>
<td>0.44</td>
<td>0.47</td>
<td>0.65</td>
<td>0.35</td>
<td>0.38</td>
<td>0.07</td>
<td>0.60</td>
<td>0.50</td>
<td>0.13</td>
<td>0.5</td>
<td>0.45</td>
<td>0.43</td>
</tr>
<tr>
<td>Standardised senna</td>
<td>0.13</td>
<td>0.25</td>
<td>0.06</td>
<td>0.29</td>
<td>0.15</td>
<td>0.27</td>
<td>0.31</td>
<td>0.31</td>
<td>0.22</td>
<td>0.28</td>
<td>0.06</td>
<td>0.13</td>
<td>0.28</td>
<td>0.21</td>
</tr>
</tbody>
</table>

There was an almost identical mean latent period between administration and activity for both drugs, (Table V). The individual latent periods for the two drugs showed wide variation. These ranged from less than 8 to more than 24 hours.

There was no difference in the overall incidence of side-effects for the two drugs, (Table VI). The range of side-effects was similar in the two groups and most were directly related to the action of the drugs on the large bowel. Sodium picosulphate might have induced fainting in 1 patient by causing fluid and electrolyte depletion. However, urea electrolytes checked at the beginning and end of treatment were normal. It seems much more likely that the sign was coincidental rather than related to treatment.

Table V. Median time (hrs.) to first bowel action for patients having an action on each particular day

<table>
<thead>
<tr>
<th>Median time (hrs.) to first bowel action for patients having an action on each particular day</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. patients</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>23</td>
</tr>
<tr>
<td>Day 1</td>
</tr>
<tr>
<td>Day 2</td>
</tr>
<tr>
<td>Day 3</td>
</tr>
<tr>
<td>Day 4</td>
</tr>
<tr>
<td>Day 5</td>
</tr>
<tr>
<td>Day 6</td>
</tr>
<tr>
<td>Day 7</td>
</tr>
<tr>
<td>Day 8</td>
</tr>
<tr>
<td>Day 9</td>
</tr>
<tr>
<td>Day 10</td>
</tr>
<tr>
<td>Day 11</td>
</tr>
<tr>
<td>Day 12</td>
</tr>
<tr>
<td>Day 13</td>
</tr>
<tr>
<td>Overall</td>
</tr>
<tr>
<td>Range</td>
</tr>
</tbody>
</table>

Consideration of the first and second weeks of treatment separately reveals that side-effects from sodium picosulphate were significantly more common in the first week. This might well relate to the higher initial dose of the drug used in treatment.
Table VI. Side-effects (no. patients)

<table>
<thead>
<tr>
<th>Side-effect</th>
<th>Sodium picosulphate</th>
<th>Standardised senna</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Incontinence</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Colic</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Very offensive motion</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Discomfort</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Patients with side-effects:
- Total number: 8
- Number reported in Week 1: 8*
- Number reported in Week 2: 6

*Standardised error of difference = 10.3%, p < 0.05

Discussion

This study confirms the conclusion of previous investigations that sodium picosulphate is an effective laxative and provides evidence that it is just as effective in elderly disabled patients as in fit younger subjects. It also suggests that the drug compares favourably with standardised senna, an agent of proven efficacy in old age.8

Earlier investigations on rats suggest that sodium picosulphate did not undergo hydrolysis and the intact molecule was responsible for the laxative activity.12 Further investigations, however, by Jauch, Hankwitz, Beschke and Pelzer9 using a more sensitive analytical method have shown that sodium picosulphate is hydrolysed by the colonic microflora to bis-(p-hydroxyphenyl)-pyridyl-2-methane which is then responsible for the laxative activity. Investigations are also currently underway to see what effect antibiotic treatment may have on the laxative activity in man.

It was hoped that the present investigation might provide data on the most appropriate dose of sodium picosulphate for the elderly. The wide individual variation in response makes any such generalisation impossible. Two factors may well have been responsible for the variation. One problem was that the initial dose of sodium picosulphate sometimes proved to be too effective, leading nursing staff to discontinue the drug for several days rather than merely reduce dosage. The other difficulty is that the elderly chronic sick represent a very heterogeneous population. Multiple pathology is common and there is wide variation in the extent to which they are disabled by mental or physical impairment. All that can be suggested is that an initial dose of 20 ml. (10 mg.) may be too powerful in some elderly patients. It might be better to start with either 10 or 15 ml. but increase this if it proves to be insufficient. The liquid presentation of sodium picosulphate makes such titration relatively simple.

Another important issue is the frequency of bowel evacuation that should be considered desirable in old age. Physicians and nurses often aim at achieving one
A comparison of sodium picosulphate ('Laxoberal') with standardised senna ('Senokot')
in geriatric patients

Evacuation per day. However, many fit elderly men and women pass motions less
often than this. A more useful guide to laxative dosage might be whether it was
sufficient to prevent the recurrence of faecal impaction and whether or not it
produced symptoms related to excessive stimulation of the colon. In the present
study, for example, it is doubtful whether patients on either sodium picosulphate
or standardised senna would have benefitted by increasing dosage to achieve daily
bowel evacuation. It is likely that the incidence of local side-effects would have
been considerably increased.

Loose or unformed bowel motions seemed to be particularly associated with the
administration of sodium picosulphate. This phenomenon did not appear to be
dose related in that reduction in the dose of the laxative did not affect the incidence
of the condition. It may be that the drug, in addition to causing colonic irritation,
reduces the absorption of water from the colon. Whatever their cause, the loose
motions do not appear to have been a major source of inconvenience. Indeed, they
may have presented a considerable advantage to ill and disabled patients to whom
straining at stool can be both hazardous and exhausting.

The mean delay of 15 hours between the administration and onset of action for
sodium picosulphate is merely a reflection that it acts on the colon following transit
through the gut. There is no evidence of its absorption intact in the upper intestine
and its action on the colon through the blood stream. The wide range for the
delay period is, in turn, related to the wide variation in gastro-intestinal transit
times in old age. Whereas, in some cases, the agent arrived at the colon in 8 hours,
in others, it took over 24 hours to cover the same distance.

The variation in the latent period of polyphenolic laxatives has important
practical implications in the elderly. Administration of the agent in the evening
does not always result in defaecation the following morning. This may sometimes
occur in the afternoon or even the following evening. Adjustment of the time for
administration may be necessary in establishing evacuation at a time convenient for
both nursing staff and patient.

Assessment of patients for side-effects from sodium picosulphate confirms the
impression of previous investigations that systemic toxicity is extremely rare. This
contrasts with unconjugated phenolphthalein where skin sensitivity and even
encephalitis may be encountered. This probably relates to differences in the extent
to which the two substances are absorbed from the gut.

Both sodium picosulphate and standardised senna frequently produced side-
effects related to their action on the colon. It is interesting to note, however, that
there was a considerable fall in the incidence of these during the second week of
administration for sodium picosulphate. This indicates that had the initial dosage
of the drug been lower there might have been a considerable reduction in unpleasant
symptoms without any important alteration in its efficacy. The limited data avail-
able here suggests that sodium picosulphate might, in appropriate doses, be slightly
less liable to cause side-effects than standardised senna. Any difference, however,
is pretty marginal.

Sodium picosulphate, then, is as effective as standardised senna in controlling
constipation in sick elderly patients. Its property of producing soft stools may well
be a positive advantage in this sort of population. Side-effects are marginally less common than those of standardised senna. The drug can, therefore, be recommended as a useful addition to the wide range of substances available for the management of bowel disorders in the elderly.

Acknowledgements
We are grateful to the nursing staff of Ashurst and Moorgreen Hospitals for the time and effort they expended in recording the effects of the laxatives used in the study.

References